Chemical Treatment for Osteoporosis

 

Executive Summary

 

Currently available therapeutics for osteoporosis have the potential to produce severe negative side effects or are required to be administered via injection. Researchers at Michigan State University have developed a new therapeutic that overcomes these challenges.

 

Description of Technology

 

This novel MSU technology uses high molecular weight polyethylene glycol (HMW-PEG) to treat osteoporosis. HMW-PEG has been previously shown to enhance GI mucinous and cytoskeletal barriers that prevent pathogenic gut bacteria from interacting with or invading the gut wall at points of weakness leading to systemic inflammation. Inflammation has been linked to bone loss leading to osteoporosis. Here, the inventor has demonstrated that HMW-PEG has positive effects on bone formation in mice. This novel therapeutic is administered orally and is also suitable for animal health.

 

Key Benefits

  • Minimal side effects
  • Easy delivery - orally taken
  • Promotes bone formation 

 

Applications

  • Osteoporosis treatment
  • Bone degeneration conditions

 

Patent Status:

 

PCT/US2014/028832

 

Licensing Rights Available

 

Field specific licensing rights available for use in animal health.

 

Inventors: Laura McCabe, Rifat Pamukcu

 

Tech ID: TEC2013-0086

 

 

Patent Information:

For Information, Contact:

Anne DiSante
Associate Director
Michigan State University
disante@msu.edu
Keywords: